• Grazoprevir hydrate in Reliable HCV Assays

  2026-09-02

  Grazoprevir hydrate (SKU C8713) offers a practical, mechanistically defined tool for studying HCV NS3/4A protease inhibition alongside cell viability and cytotoxicity measurements. This scenario-based guide explains stock preparation, assay compatibility, EC50 interpretation, clinical translation limits, and evidence-based supplier selection.

• FXR–KLF11 Signaling in Contrast-Induced AKI

  2026-09-02

  A 2026 study identifies an FXR–KLF11 transcriptional axis that protects against contrast-induced acute kidney injury by suppressing JAK2/STAT3 signaling. Using mouse, cellular, transcriptomic, promoter-reporter, ChIP, and genetic approaches, the work provides a mechanistic framework for evaluating CDCA as a preclinical renoprotective intervention.

• Elobixibat Hydrate: From IBAT to Motility Assays

  2026-09-01

  Elobixibat hydrate is an ileal bile acid transporter inhibitor whose value extends beyond constipation research. This article connects IBAT pharmacology with pressure-based peristalsis assays, clarifying how to separate transporter-driven effects from downstream enteric mechanisms.

• Small Molecule Inhibitor: CK2/ERK8 Workflow

  2026-08-31

  Build reproducible kinase inhibition, phosphorylation, and exploratory condensate assays around a defined dual-target chemical probe. This workflow distinguishes validated CK2/ERK8 applications from hypothesis-generating studies inspired by viral nucleocapsid phase separation research.

• CDK9 inhibitor (A3294): Practical Workflow Guide

  2026-08-31

  CDK9 inhibitor (A3294) is a selective serine/threonine kinase inhibitor for studying CDK9-dependent transcription elongation, positive elongation factor b (P-TEFb) inhibition, and HIV-1 propagation inhibition. It should not be used as a pan-CDK reagent, a universal cytotoxicity control, or a long-term working-solution storage product.

• EZ Cap™ Cas9 mRNA (5-moUTP) for Neurodegeneration

  2026-08-30

  EZ Cap™ Cas9 mRNA (5-moUTP) supports transient CRISPR-Cas9 genome editing for mechanistic neurodegeneration studies. This article translates the Fyn–Stat3 zebrafish findings into practical assay decisions while distinguishing product capabilities from evidence that still requires experimental validation.

• p21-ELP1-Bac Suppresses Glioblastoma Proliferation

  2026-08-29

  The reference study evaluates p21-ELP1-Bac, an elastin-like polypeptide and cell-penetrating peptide delivery system for a p21-derived cell-cycle inhibitor, in three glioblastoma models. Its findings support intracellular delivery and predominantly cytostatic suppression of proliferation, while revealing cell-line differences in sensitivity and apoptosis.

• Ziprasidone Hydrochloride: Mechanism & Research

  2026-08-28

  Ziprasidone HCl is a second-generation antipsychotic agent used in receptor pharmacology and neuroscience research, with reported GOT1 inhibition and exploratory antitumor activity. The strongest translational evidence supports psychiatric use, while pancreatic cancer applications remain preclinical and require independent validation.

• L-Threonine: From Nutrient Flux to Translational Insight

  2026-08-28

  L-Threonine is more than a medium component: it is a tractable variable for studying protein synthesis, amino acid sensing, metabolic flux, and translational assay quality. This perspective connects nutrient engineering with metal-free nanozyme validation while defining practical controls and limits.

• CLCC1 and Herpesvirus Nuclear Egress

  2026-08-28

  A herpes simplex virus 1 CRISPR screen identifies CLCC1 as a host factor required for the membrane fusion step of nuclear egress. CLCC1 loss traps capsid-containing vesicles near the nucleus, reduces viral production, and disrupts nuclear pore complex insertion in uninfected cells, linking viral egress to broader nuclear-envelope morphogenesis.

• Balsalazide disodium: IBD Research Workflows

  2026-08-27

  Balsalazide disodium combines colon-targeted 5-ASA biology with practical applications in inflammation research, immunology assays, animal models, and radiotracer development. This guide translates reported labeling conditions and formulation data into reproducible workflows, controls, and troubleshooting decisions.

• (-)-JQ1: The Control That Makes BET Data Translational

  2026-08-27

  (-)-JQ1 is more than an inactive stereoisomer: it is a strategic control for separating BET bromodomain engagement from downstream transcriptional and survival phenotypes. This article connects rigorous JQ1 assay design with mechanistic lessons from inv(16) AML and the N-MYC/eIF4G1 axis.

• Novel Methylene Ziprasidone Dimer Impurity

  2026-08-26

  Murkute et al. identified and structurally characterized a previously unreported methylene ziprasidone dimer that appeared during scale-up of ziprasidone hydrochloride synthesis. The study demonstrates how preparative HPLC, high-resolution mass spectrometry, and multidimensional NMR can convert an HPLC-UV signal into a defined impurity suitable for process and quality-control assessment.

• CTOP for Reliable μ-Opioid Mechanism Studies

  2026-08-26

  This scenario-based guide explains how CTOP (SKU B5135) can strengthen μ-opioid receptor mechanism studies, especially when viability, proliferation, or pain-related phenotypes are difficult to interpret. It covers experimental controls, peptide handling, circuit-level interpretation, and practical vendor-selection criteria.

• Deferiprone Workflows for Iron-Stress Research

  2026-08-25

  Build controlled iron-deficiency, oxidative-stress, inflammation, and apoptosis assays with water-soluble Deferiprone. This workflow connects enterocyte metabolomics to cancer biology, doxorubicin-response studies, and neurovascular models while emphasizing controls, timing, and troubleshooting.

453 records 6/31 page Previous Next First page 上5页 678910 下5页 Last page